We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-3.25%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$484M
AUM Growth
-$132M
Cap. Flow
-$82.1M
Cap. Flow %
-16.96%
Top 10 Hldgs %
59.62%
Holding
44
New
11
Increased
12
Reduced
4
Closed
16

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$26.7M
2
BIIB icon
Biogen
BIIB
+$20.2M
3
TVTX icon
Travere Therapeutics
TVTX
+$16.4M
4
EXEL icon
Exelixis
EXEL
+$16.4M
5
NVRO
NEVRO CORP.
NVRO
+$13.1M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$45M
2
ZYME icon
Zymeworks
ZYME
+$37.8M
3
VCEL icon
Vericel Corp
VCEL
+$27.8M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$25.8M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 94.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GERN icon
26
Geron
GERN
$828M
$4.12M 0.85%
2,610,000
-2,445,189
-48% -$4.37M
SYRE icon
27
Spyre Therapeutics
SYRE
$8.54B
$3.98M 0.82%
+20,116
New +$3.86M
TCDA
28
DELISTED
Tricida, Inc. Common Stock
TCDA
$1.85M 0.38%
+349,600
New +$2.2M
ARVN icon
29
Arvinas
ARVN
$518M
– –
-164,150
Closed -$13.9M
AUPH icon
30
Aurinia Pharmaceuticals
AUPH
$1.91B
– –
-175,000
Closed -$2.42M
KYNB
31
CALL
Kyntra Bio
KYNB
$27.2M
– –
-6,660
Closed -$6.18M
IONS icon
32
Ionis Pharmaceuticals
IONS
$8.6B
– –
-75,000
Closed -$4.24M
MRSN
33
DELISTED
Mersana Therapeutics
MRSN
– –
-19,498
Closed -$13M
PRTA icon
34
Prothena Corp
PRTA
$425M
– –
-977,647
Closed -$11.7M
SPRY icon
35
ARS Pharmaceuticals
SPRY
$509M
– –
-70,000
Closed -$3.24M
TBPH icon
36
Theravance Biopharma
TBPH
$874M
– –
-824,580
Closed -$14.7M
TPST icon
37
Tempest Therapeutics
TPST
$13.7M
– –
-1,385
Closed -$578K
VCEL icon
38
Vericel Corp
VCEL
$2.35B
– –
-900,000
Closed -$27.8M
ZYME icon
39
Zymeworks
ZYME
$1.61B
– –
-799,722
Closed -$37.8M
FMTX
40
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
– –
-236,400
Closed -$8.25M
GBT
41
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-595,473
Closed -$25.8M
CALA
42
CALL
DELISTED
Calithera Biosciences, Inc
CALA
– –
-25,000
Closed -$2.46M
CALA
43
DELISTED
Calithera Biosciences, Inc
CALA
– –
-92,250
Closed -$9.06M
GWPH
44
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-390,000
Closed -$45M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2021 Portfolio in Review

As of Q1 2021, Great Point Partners held 44 positions worth $484M, down 21% from $616M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Great Point Partners withdrew a net $82.1M in Q1 2021, closing 16 positions and reducing 4 holdings. Its most notable exit was GW Pharmaceuticals Plc American Depositary Shares, an estimated $45M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Mirati Therapeutics, Inc. Common Stock worth $23.1M.

  • Great Point Partners's largest Q1 2021 buy was Mirati Therapeutics, Inc. Common Stock: 135,000 shares worth $23.1M.
  • Great Point Partners added most to Exelixis in Q1 2021, an estimated $16.4M increase.
  • Great Point Partners's biggest Q1 2021 reduction was Acadia Pharmaceuticals, cutting an estimated $18M.
  • Great Point Partners fully exited GW Pharmaceuticals Plc American Depositary Shares in Q1 2021, selling an estimated $45M.
  • Great Point Partners's ten largest holdings make up 60% of its $484M portfolio in Q1 2021.
  • Great Point Partners opened 11 new positions and closed 16 in Q1 2021.
  • Great Point Partners's portfolio value fell 21% quarter-over-quarter to $484M.

Based on Great Point Partners's 13F filing for Q1 2021, filed 17 May 2021.